Review of hypoparathyroidism

Ejigayehu G. Abate, Bart Clarke

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Hypoparathyroidism is a rare endocrine disorder in which parathyroid hormone (PTH) production is abnormally low or absent, resulting in low serum calcium and increased serum phosphorus. The most common cause of hypoparathyroidism is parathyroid gland injury or inadvertent removal during thyroid surgery. Current treatments include supplementation with calcium and active vitamin D, with goal albumin-corrected serum calcium level in the low-normal range of 8-9 mg/dl. Complications of the disease include renal dysfunction, nephrocalcinosis, kidney stones, extracellular calcifications of the basal ganglia, and posterior subcapsular cataracts, as well as low bone turnover and increased bone density. Until January 2015, hypoparathyroidism was the only classic endocrine disease without an available hormone replacement. Recombinant human PTH 1-84, full-length PTH, is now available for a selected group of patients with the disease who are not well controlled on the current standard therapy of calcium and active vitamin D. In addition, the role of PTH replacement on quality of life, intracerebral calcifications, cataracts, improving bone turnover, and reduction of renal complications of the disease remains to be further investigated.

Original languageEnglish (US)
Article number172
JournalFrontiers in Endocrinology
Volume7
Issue numberJAN
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hypoparathyroidism
Parathyroid Hormone
Calcium
Bone Remodeling
Vitamin D
Cataract
Nephrocalcinosis
Kidney
Endocrine System Diseases
Parathyroid Glands
Kidney Calculi
Basal Ganglia
Serum
Serum Albumin
Bone Density
Phosphorus
Thyroid Gland
Reference Values
Quality of Life
Hormones

Keywords

  • Hypocalcemia
  • Hypoparathyroidism
  • Natpara
  • Parathyroid hormone
  • PTH (1-84)

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Review of hypoparathyroidism. / Abate, Ejigayehu G.; Clarke, Bart.

In: Frontiers in Endocrinology, Vol. 7, No. JAN, 172, 01.01.2017.

Research output: Contribution to journalReview article

Abate, Ejigayehu G. ; Clarke, Bart. / Review of hypoparathyroidism. In: Frontiers in Endocrinology. 2017 ; Vol. 7, No. JAN.
@article{393c847654e94b36a4b23bbd2d4dfe80,
title = "Review of hypoparathyroidism",
abstract = "Hypoparathyroidism is a rare endocrine disorder in which parathyroid hormone (PTH) production is abnormally low or absent, resulting in low serum calcium and increased serum phosphorus. The most common cause of hypoparathyroidism is parathyroid gland injury or inadvertent removal during thyroid surgery. Current treatments include supplementation with calcium and active vitamin D, with goal albumin-corrected serum calcium level in the low-normal range of 8-9 mg/dl. Complications of the disease include renal dysfunction, nephrocalcinosis, kidney stones, extracellular calcifications of the basal ganglia, and posterior subcapsular cataracts, as well as low bone turnover and increased bone density. Until January 2015, hypoparathyroidism was the only classic endocrine disease without an available hormone replacement. Recombinant human PTH 1-84, full-length PTH, is now available for a selected group of patients with the disease who are not well controlled on the current standard therapy of calcium and active vitamin D. In addition, the role of PTH replacement on quality of life, intracerebral calcifications, cataracts, improving bone turnover, and reduction of renal complications of the disease remains to be further investigated.",
keywords = "Hypocalcemia, Hypoparathyroidism, Natpara, Parathyroid hormone, PTH (1-84)",
author = "Abate, {Ejigayehu G.} and Bart Clarke",
year = "2017",
month = "1",
day = "1",
doi = "10.3389/fendo.2016.00172",
language = "English (US)",
volume = "7",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - Review of hypoparathyroidism

AU - Abate, Ejigayehu G.

AU - Clarke, Bart

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Hypoparathyroidism is a rare endocrine disorder in which parathyroid hormone (PTH) production is abnormally low or absent, resulting in low serum calcium and increased serum phosphorus. The most common cause of hypoparathyroidism is parathyroid gland injury or inadvertent removal during thyroid surgery. Current treatments include supplementation with calcium and active vitamin D, with goal albumin-corrected serum calcium level in the low-normal range of 8-9 mg/dl. Complications of the disease include renal dysfunction, nephrocalcinosis, kidney stones, extracellular calcifications of the basal ganglia, and posterior subcapsular cataracts, as well as low bone turnover and increased bone density. Until January 2015, hypoparathyroidism was the only classic endocrine disease without an available hormone replacement. Recombinant human PTH 1-84, full-length PTH, is now available for a selected group of patients with the disease who are not well controlled on the current standard therapy of calcium and active vitamin D. In addition, the role of PTH replacement on quality of life, intracerebral calcifications, cataracts, improving bone turnover, and reduction of renal complications of the disease remains to be further investigated.

AB - Hypoparathyroidism is a rare endocrine disorder in which parathyroid hormone (PTH) production is abnormally low or absent, resulting in low serum calcium and increased serum phosphorus. The most common cause of hypoparathyroidism is parathyroid gland injury or inadvertent removal during thyroid surgery. Current treatments include supplementation with calcium and active vitamin D, with goal albumin-corrected serum calcium level in the low-normal range of 8-9 mg/dl. Complications of the disease include renal dysfunction, nephrocalcinosis, kidney stones, extracellular calcifications of the basal ganglia, and posterior subcapsular cataracts, as well as low bone turnover and increased bone density. Until January 2015, hypoparathyroidism was the only classic endocrine disease without an available hormone replacement. Recombinant human PTH 1-84, full-length PTH, is now available for a selected group of patients with the disease who are not well controlled on the current standard therapy of calcium and active vitamin D. In addition, the role of PTH replacement on quality of life, intracerebral calcifications, cataracts, improving bone turnover, and reduction of renal complications of the disease remains to be further investigated.

KW - Hypocalcemia

KW - Hypoparathyroidism

KW - Natpara

KW - Parathyroid hormone

KW - PTH (1-84)

UR - http://www.scopus.com/inward/record.url?scp=85011883630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011883630&partnerID=8YFLogxK

U2 - 10.3389/fendo.2016.00172

DO - 10.3389/fendo.2016.00172

M3 - Review article

VL - 7

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - JAN

M1 - 172

ER -